J&J sees room to broaden US robotic surgery market with Ottava
· shani alexander
AI Briefing
- • Johnson & Johnson's Ottava robotic surgery system has FDA de novo authorization for multiple procedures.
- • Low US market penetration leaves Ottava well-positioned to broaden adoption.
- • Ottava to be launched in the US, initially in paid plans.
Source Summary
Johnson & Johnson believes that the low penetration of the soft tissue robotics market in the U.S. leaves its Ottava robotic surgical system well placed to broaden adoption. New Brunswick, N.J.-based J&J was granted FDA de novo authorization for Ottava last month, clearing the device for multiple procedures in general surgery. The company plans to launch the system first in the U.S.
Advertisement